US 12,391,959 B2
Adenoviral vectors comprising partial deletions of E3
Hildegund C. J. Ertl, Villanova, PA (US); and Xiang Yang Zhou, North Wales, PA (US)
Assigned to The Wistar Institute, Philadelphia, PA (US)
Filed by THE WISTAR INSTITUTE, Philadelphia, PA (US)
Filed on May 31, 2023, as Appl. No. 18/203,818.
Application 18/203,818 is a continuation of application No. 17/037,966, filed on Sep. 30, 2020, granted, now 11,702,675.
Application 17/037,966 is a continuation of application No. 16/530,359, filed on Aug. 2, 2019, granted, now 10,822,619, issued on Nov. 3, 2020.
Application 16/530,359 is a continuation of application No. 15/453,579, filed on Mar. 8, 2017, granted, now 10,407,696, issued on Sep. 10, 2019.
Application 15/453,579 is a continuation of application No. 14/190,787, filed on Feb. 26, 2014, granted, now 9,624,510, issued on Apr. 18, 2017.
Claims priority of provisional application 61/771,370, filed on Mar. 1, 2013.
Prior Publication US 2023/0304042 A1, Sep. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/86 (2006.01); A61K 39/21 (2006.01); C12N 15/861 (2006.01); A61K 39/00 (2006.01); A61K 39/015 (2006.01); A61K 39/04 (2006.01); A61K 39/29 (2006.01)
CPC C12N 15/86 (2013.01) [A61K 39/21 (2013.01); C12N 15/861 (2013.01); A61K 39/015 (2013.01); A61K 39/04 (2013.01); A61K 39/29 (2013.01); A61K 2039/5256 (2013.01); C12N 2710/10043 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/10352 (2013.01); C12N 2740/16134 (2013.01); C12N 2800/24 (2013.01)] 6 Claims
 
1. A method of inducing an immune response to an antigenic protein in a subject, comprising administering to the subject an immunogenic composition comprising a replication-incompetent adenovirus vector comprising:
a) open reading frame (ORF) ORF1 and ORF2 of E3 genomic region;
b) selective deletion of E3 genomic region consisting of ORF3, ORF4, ORF5, ORF6, and ORF7;
c) at least one ORF selected from the group consisting of ORF8 and ORF9; and
d) at least one ORF encoding the antigenic protein.